(Q37780016)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709651%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

review article

1 reference

title

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709651%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709651%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Jesús García-Foncillas

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709651%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

1 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709651%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Translational Oncology

10 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709651%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709651%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709651%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

533-542

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709651%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12094-010-0551-3

10 February 2020

exact match

0 references

cites work

Metastatic colorectal cancer-past, progress and future

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-010-0551-3

Practical questions in liver metastases of colorectal cancer: general principles of treatment

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-010-0551-3

Combining chemotherapy and targeted therapies in metastatic colorectal cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-010-0551-3

Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome

21 January 2018

1 reference

12 December 2020

Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer

1 reference

12 December 2020

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

12 December 2020

Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer.

1 reference

12 December 2020

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

1 reference

12 December 2020

Cancer statistics, 2005

1 reference

12 December 2020

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

12 December 2020

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases

1 reference

12 December 2020

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

12 December 2020

The continuum of care: a paradigm for the management of metastatic colorectal cancer

1 reference

12 December 2020

Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK

1 reference

12 December 2020

Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline

1 reference

12 December 2020

Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management

1 reference

12 December 2020

Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer

1 reference

12 December 2020

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

12 December 2020

Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas

1 reference

12 December 2020

Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?

1 reference

12 December 2020

Global cancer statistics, 2002

1 reference

12 December 2020

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

12 December 2020

Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer--too good to be true?

1 reference

12 December 2020

Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

1 reference

12 December 2020

CDX-2 expression in pulmonary fine-needle aspiration specimens: a useful adjunct for the diagnosis of metastatic colorectal adenocarcinoma

1 reference

12 December 2020

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

12 December 2020

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

12 December 2020

Therapy for metastatic colorectal cancer

1 reference

12 December 2020

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

12 December 2020

Systemic therapy for metastatic colorectal cancer: current options, current evidence

1 reference

12 December 2020

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

12 December 2020

Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer

1 reference

12 December 2020

Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience

1 reference

12 December 2020

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

1 reference

12 December 2020

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

1 reference

12 December 2020

Cetuximab: clinical results in colorectal cancer.

1 reference

12 December 2020

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

12 December 2020

Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis

1 reference

12 December 2020

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

1 reference

12 December 2020

Panitumumab in colon cancer: a review and summary of ongoing trials

1 reference

12 December 2020

The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer

1 reference

12 December 2020

KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer.

1 reference

12 December 2020

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

1 reference

12 December 2020

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

1 reference

12 December 2020

Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications

1 reference

12 December 2020

The integration of targeted agents into systemic therapy of metastatic colorectal cancer.

1 reference

12 December 2020

Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review.

1 reference

12 December 2020

Cancer incidence and mortality in Europe, 2004

1 reference

12 December 2020

Neoadjuvant chemotherapy for metastatic colorectal cancer to the liver: from chemotherapy to targeting therapy

1 reference

12 December 2020

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

12 December 2020

Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients

1 reference

12 December 2020

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

12 December 2020

International trends in colorectal cancer incidence rates

1 reference

12 December 2020

Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.

1 reference

12 December 2020

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

1 reference

12 December 2020

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

12 December 2020

Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience.

1 reference

12 December 2020

Evaluation of serum carcinoembryonic antigen monitoring in the follow-up of colorectal cancer patients with metastatic lymph nodes and a normal preoperative serum level

1 reference

12 December 2020

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

12 December 2020

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

1 reference

12 December 2020

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

12 December 2020

KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology

1 reference

12 December 2020

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

1 reference

12 December 2020

FDG-PET in colorectal cancer

1 reference

12 December 2020

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

12 December 2020

Alternative dosing schedules for cetuximab: a role for biweekly administration?

1 reference

12 December 2020

Application of COLD-PCR for improved detection of KRAS mutations in clinical samples

1 reference

12 December 2020

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

1 reference

12 December 2020

Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells

1 reference

12 December 2020

Management of liver metastases from colorectal cancer.

1 reference

12 December 2020

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

12 December 2020

Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography

1 reference

12 December 2020

Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?

1 reference

12 December 2020

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.

1 reference

12 December 2020

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

12 December 2020

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

12 December 2020

Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy

1 reference

12 December 2020

Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies

1 reference

12 December 2020

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

12 December 2020

Cetuximab-induced hypomagnesemia in patients with colorectal cancer.

1 reference

12 December 2020

L-arginine as a factor increasing arginase significance in diagnosis of primary and metastatic colorectal cancer.

1 reference

12 December 2020

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

12 December 2020

Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.

1 reference

12 December 2020

Cetuximab in the management of colorectal cancer

1 reference

12 December 2020

Colorectal carcinoma and brain metastasis: distribution, treatment, and survival.

1 reference

12 December 2020

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

12 December 2020

Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases

1 reference

12 December 2020

Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer

1 reference

12 December 2020

1 reference

12 December 2020

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer

1 reference

12 December 2020

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.

1 reference

12 December 2020

Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity

1 reference

12 December 2020

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

12 December 2020

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

1 reference

12 December 2020

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

12 December 2020

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

1 reference

12 December 2020

PET imaging for evaluation of metastatic colorectal cancer of the liver

1 reference

12 December 2020

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

12 December 2020

Colorectal cancer mortality in Spain: trends and projections for 1985-2019.

1 reference

12 December 2020

High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer

1 reference

12 December 2020

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer

1 reference

12 December 2020

Controversies in the management of colorectal liver metastases: role of PET and PET/CT.

1 reference

12 December 2020

10.1007/S12094-010-0551-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709651%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference